Gaucher cells are not associated with α-synuclein neuropathology in infants
- PMID: 26784964
- DOI: 10.5414/NP300901
Gaucher cells are not associated with α-synuclein neuropathology in infants
Abstract
A link between Gaucher disease (GD) and Parkinson disease (PD) has been suggested by many studies. Lewy-body-like α-synuclein inclusions have been shown in older GD patients who developed Parkinsonism. It has been proposed that decreased levels of glucocerebrosidase mediate impaired α-synuclein degradation and hence its accumulation. Nevertheless, this phenomenon is less investigated in the infantile form of GD. The aim of the study was to evaluate α-synuclein and τ-pathology in the brain and non-neural tissues (liver, spleen, pancreas, myocardial muscle, and lung) of 5 infants (age range from 1 month to 4 years) with GD. Our immunohistochemical study did not provide evidence that pathological α-synuclein or τ-accumulates early in tissues where Gaucher cells are already prominently present. Although recent finding of altered plasma α-synuclein levels in infantile GD patients suggest an early imbalance of α-synuclein homeostasis, our findings indicate that this does not inevitably coincide with α-synuclein pathology in the brain. Understanding this temporal variance of plasma levels and brain accumulation of α-synuclein might also be important when interpreting blood-based α-synuclein assays for the diagnosis of PD.
Similar articles
-
A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.J Neurosci. 2016 Jul 13;36(28):7441-52. doi: 10.1523/JNEUROSCI.0636-16.2016. J Neurosci. 2016. PMID: 27413154 Free PMC article.
-
A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease.Neurobiol Dis. 2020 Feb;134:104647. doi: 10.1016/j.nbd.2019.104647. Epub 2019 Nov 10. Neurobiol Dis. 2020. PMID: 31669751 Free PMC article.
-
Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease.Mov Disord. 2015 Jun;30(7):989-91. doi: 10.1002/mds.26200. Epub 2015 May 12. Mov Disord. 2015. PMID: 25962734
-
A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.Biochim Biophys Acta. 2009 Jul;1792(7):730-40. doi: 10.1016/j.bbadis.2008.07.006. Epub 2008 Aug 5. Biochim Biophys Acta. 2009. PMID: 18718530 Review.
-
Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.Prog Neurobiol. 2015 Feb;125:47-62. doi: 10.1016/j.pneurobio.2014.12.001. Epub 2015 Jan 6. Prog Neurobiol. 2015. PMID: 25573151 Review.
Cited by
-
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.Front Mol Neurosci. 2022 Aug 3;15:934820. doi: 10.3389/fnmol.2022.934820. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35992201 Free PMC article. Review.
-
Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism.Int J Mol Sci. 2022 May 23;23(10):5842. doi: 10.3390/ijms23105842. Int J Mol Sci. 2022. PMID: 35628652 Free PMC article. Review.
-
The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.Neuron. 2017 Feb 22;93(4):737-746. doi: 10.1016/j.neuron.2017.01.018. Neuron. 2017. PMID: 28231462 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
